BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9352743)

  • 1. Use of high-dose chemotherapy plus granulocyte colony-stimulating factor for the salvage of refractory or resistant-relapse lymphoma patients without stem cell support.
    Koç H; Arslan O; Gürman G; Akan H; Ozcan M; Ilhan O; Aydoğdu I; Arat M; Beksaç M; Konuk N; Uysal A
    Acta Haematol; 1997; 98(3):136-9. PubMed ID: 9352743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
    Mabed M; Al-Kgodary T
    Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
    Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ
    Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD
    Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
    Long GD; Negrin RS; Hoyle CF; Kusnierz-Glaz CR; Schriber JR; Blume KG; Chao NJ
    Cancer; 1995 Sep; 76(5):860-8. PubMed ID: 8625190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.
    Taylor KM; Jagannath S; Spitzer G; Spinolo JA; Tucker SL; Fogel B; Cabanillas FF; Hagemeister FB; Souza LM
    J Clin Oncol; 1989 Dec; 7(12):1791-9. PubMed ID: 2479719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
    Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki D; Sklar J; Barcos M; Peterson BA
    Leuk Lymphoma; 2001; 42(6):1255-64. PubMed ID: 11911406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.